21-Apr-2026
Guggenheim Sticks to Their Buy Rating for InflaRx (IFRX)
TipRanks (Tue, 21-Apr 7:21 AM ET)
Globe Newswire (Thu, 9-Apr 7:30 AM ET)
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
Globe Newswire (Tue, 31-Mar 7:30 AM ET)
Globe Newswire (Mon, 30-Mar 7:30 AM ET)
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
Globe Newswire (Thu, 19-Mar 7:30 AM ET)
Globe Newswire (Wed, 18-Mar 7:30 AM ET)
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Globe Newswire (Fri, 13-Mar 5:00 PM ET)
InflaRx to Report Full Year 2025 Results on March 19, 2026
Globe Newswire (Thu, 12-Mar 7:30 AM ET)
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
Globe Newswire (Thu, 26-Feb 7:30 AM ET)
InflaRx Announces Participation in February Investor Conferences
Globe Newswire (Thu, 29-Jan 7:30 AM ET)
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Inflarx N.V. trades on the NASDAQ stock market under the symbol IFRX.
As of April 21, 2026, IFRX stock price climbed to $1.73 with 1,273,857 million shares trading.
IFRX has a beta of 1.85, meaning it tends to be more sensitive to market movements. IFRX has a correlation of 0.04 to the broad based SPY ETF.
IFRX has a market cap of $117.20 million. This is considered a Micro Cap stock.
Last quarter Inflarx N.V. reported $-39,501 in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-269,501 and exceeded earnings estimates by $.01.
In the last 3 years, IFRX traded as high as $5.20 and as low as $.71.
IFRX has outperformed the market in the last year with a price return of +51.8% while the SPY ETF gained +38.4%. IFRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +73.0% and +78.9%, respectively, while the SPY returned +3.0% and +6.8%, respectively.
IFRX support price is $1.54 and resistance is $1.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IFRX shares will trade within this expected range on the day.